Morgan Stanley Expansion Capital Leads $33 Million Growth Financing For Subtle Medical
Morgan Stanley Expansion Capital Leads $33 Million Growth Financing For Subtle Medical
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Key Terms
artificial intelligencetechnical
Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.
mrimedical
Magnetic resonance imaging (MRI) is a medical scan that uses magnetic fields and radio waves to create detailed pictures of the inside of the body, like a high-resolution camera for tissues and organs. Investors care because MRI drives demand for imaging machines, hospital services, diagnostics and can be central to clinical trial results and regulatory decisions—changes in MRI use or technology can affect revenue, capital spending and reimbursement in healthcare and medical device markets.
petmedical
Positron emission tomography (PET) is a medical imaging test that creates a live map of how organs and tissues are working by tracking a tiny, safe amount of radioactive tracer inside the body. For investors, PET matters because it’s often used in clinical trials and diagnosis to show whether a drug or treatment is affecting disease — think of it as a performance meter that can speed regulatory decisions, change market forecasts, and affect a product’s commercial value.
fda-clearedregulatory
FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.
vendor-neutraltechnical
Vendor-neutral describes products, systems, or standards that are not tied to a single supplier, allowing different companies’ offerings to work together or be swapped without major changes. For investors, vendor-neutral solutions reduce the risk of costly vendor lock-in, support competition and easier upgrades, and can protect value by making a business more flexible and less dependent on one supplier—similar to buying furniture that fits any room rather than a custom built-in.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
NEW YORK--(BUSINESS WIRE)--
Morgan Stanley Investment Management announced today that funds managed by Morgan Stanley Expansion Capital have led a $33 million growth financing for Subtle Medical (the Company), a medical imaging software company using artificial intelligence to improve imaging workflow efficiency and image quality across MRI, PET and CT. The financing included participation from Shinhan Venture Investment and existing investors Fusion Fund, EnvisionX, BRV, and Samsung Ventures, bringing Subtle Medical’s total capital raised to $86 million.
Based in Menlo Park, CA, Subtle Medical develops vendor-neutral software designed to operate across existing imaging equipment, regardless of manufacturer. Its solutions are used by hospitals and imaging centers to support scan-time reduction, image enhancement, dose optimization and imaging standardization workflows without requiring immediate replacement of existing scanner infrastructure.
“Medical imaging is a critical component of healthcare delivery and is under increasing operational pressure from rising scan volumes, capacity constraints and aging infrastructure,” said Kevin Han, Executive Director at Morgan Stanley Expansion Capital. “We believe Subtle Medical’s software platform addresses a clear market need by helping providers improve utilization of existing imaging assets, support clinical quality and expand patient access.”
The financing is expected to support Subtle Medical’s continued product development and commercial expansion across the United States and international markets. Subtle Medical’s portfolio includes 11 FDA-cleared software products for MRI, PET and CT workflows, and its technology is deployed on more than 1,300 scanners globally. The Company also continues to develop its AI Imaging Hub, a vendor-neutral platform intended to help providers manage imaging performance across modalities and scanner fleets.
“This is a meaningful moment for Subtle Medical. We have clinical validation, a growing installed base, and a platform architecture that scales across modalities – and now the capital and partnership to accelerate that globally,” said newly appointed Subtle Medical CEO, Ohad Arazi. “Morgan Stanley Expansion Capital brings a long-term perspective with broad healthcare experience that will be valuable as we expand adoption across modalities and geographies.”
Subtle Medical’s approach reflects a broader shift toward software-based infrastructure in healthcare, where providers are increasingly seeking tools that can improve productivity, interoperability and access while extending the value of existing capital equipment.
About Subtle Medical
Subtle Medical is a leading provider of AI-powered imaging solutions, optimizing scanner efficiency and image quality across radiology. Recognized by TIME on its World's Top HealthTech Companies of 2025 list and multiple times by CB Insights as a GenAI 50, Digital Health 150, and Top AI 100 company, Subtle Medical is committed to transforming medical imaging through intelligent software solutions. The company's products are deployed on over 1000 scanners worldwide, helping imaging centers and hospitals deliver faster scans, improved image quality, and better patient care, without the need for new hardware. Learn more at www.subtlemedical.com.
About Shinhan Venture Investment
Shinhan Venture Investment is a Seoul-based venture capital firm and affiliate of Shinhan Financial Group (NYSE: SHG), one of Korea's leading financial institutions. Founded in 2000, Shinhan Venture Investment focuses on early-to-growth stage investments across technology, healthcare, and other high-growth sectors, leveraging the financial network and resources of Shinhan Financial Group to support a portfolio of over 160 investments in domestic and international markets.
About Morgan Stanley Expansion Capital
Morgan Stanley Expansion Capital is the growth-focused private investment platform within Morgan Stanley Investment Management. Morgan Stanley Expansion Capital targets late-stage growth equity and credit investments within healthcare, technology, consumer, and other high-growth sectors. For nearly four decades, Morgan Stanley Expansion Capital has successfully pursued growth investment opportunities and has completed investments in over 220 companies, leveraging the global brand and network of Morgan Stanley.
Morgan Stanley Investment Management
Morgan Stanley Investment Management, together with its investment advisory affiliates, has more than 1,300 investment professionals around the world and $1.9 trillion in assets under management or supervision as of March 31, 2026. Morgan Stanley Investment Management strives to provide outstanding long-term investment performance, service, and a comprehensive suite of investment management solutions to a diverse client base, which includes governments, institutions, corporations and individuals worldwide. For further information about Morgan Stanley Investment Management, please visit www.morganstanley.com/im.
About Morgan Stanley
Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.
